SCHEMBL4348258

SCHEMBL4348258

CC(=O)Nc1ccc(-c2ccc3c(-c4ccc(F)cc4)n[nH]c3n2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.47
KMT2A Q03164 5/20 0.47
KDM4E B2RXH2 4/20 0.47
POLB P06746 2/20 0.47
PRNP P04156 1/20 0.47
GAA P10253 1/20 0.47
ALDH1A1 P00352 4/20 0.47
MAPT P10636 3/20 0.47
HPGD P15428 3/20 0.47
RXFP1 Q9HBX9 2/20 0.47
ADORA2A P29274 2/20 0.45
RAB9A P51151 1/20 0.45
ADORA3 P0DMS8 1/20 0.45
TTK P33981 1/20 0.45
MAPK8 P45983 1/20 0.45
PDE5A O76074 1/20 0.45
PDE1A P54750 1/20 0.45
PDE1B Q01064 1/20 0.45
PDE3B Q13370 1/20 0.45
PDE1C Q14123 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4348111 0.89 KDM4E (0.50) MEN1KMT2AKDM4EPOLBPRNP
SCHEMBL4344646 0.88 PDE5A (0.50) MEN1KMT2AKDM4EPOLBPRNP
SCHEMBL4344680 0.88 JAK3 (0.48) KDM4EALDH1A1MAPTRAB9ATTK
SCHEMBL12035332 0.86 TTK (0.48) MEN1KMT2AKDM4EPOLBPRNP
SCHEMBL4348035 0.86 GSK3B (0.57) MEN1KMT2AKDM4EPOLBPRNP
SCHEMBL4348091 0.85 KMT2A (0.45) MEN1KMT2AKDM4EPOLBPRNP
SCHEMBL4349876 0.85 MOK (0.46) MEN1KMT2AKDM4EPOLBPRNP
SCHEMBL12035350 0.85 KDM4E (0.44) MEN1KMT2AKDM4EPOLBPRNP
SCHEMBL4348340 0.84 KDM4E (0.44) MEN1KMT2AKDM4EPOLBPRNP
SCHEMBL4348246 0.84 ABL1 (0.48) MEN1KMT2AKDM4EPOLBPRNP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110312992-A1 Inhibitors of C-Kit and Uses Thereof BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-12-22 US claimed
US-20120302565-A1 KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF M.D. ANDERSON CANCER CENTER (US) 2012-11-29 US disclosed
US-8268809-B2 Kinase inhibitors for preventing or treating pathogen infection and method of use thereof EMORY UNIVERSITY (US) 2012-09-18 US disclosed
US-20110312992-A1 Inhibitors of C-Kit and Uses Thereof BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-12-22 US disclosed
US-20110312992-A1 Inhibitors of C-Kit and Uses Thereof BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-12-22 US disclosed
US-20100249122-A1 Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof EMORY UNIVERSITY (US) 2010-09-30 US disclosed
US-20090281115-A1 INHIBITORS OF C-KIT AND USES THEREOF Board of Regents, The University of Texas System, a Texas University (US) 2009-11-12 US disclosed
US-20090281115-A1 INHIBITORS OF C-KIT AND USES THEREOF Board of Regents, The University of Texas System, a Texas University (US) 2009-11-12 US disclosed
WO-2008005877-A2 INHIBITORS OF C-KIT AND USES THEREOF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249122-A1 Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof MAP3K1, MAP3K2, MAP3K6 MEN1 4195/4885KMT2A 1524/4885KDM4E 1924/4885
US-20110312992-A1 Inhibitors of C-Kit and Uses Thereof KIT, CHUK, MASTL MEN1 1273/4885KMT2A 773/4885KDM4E 702/4885
US-20120302565-A1 KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF MAP3K1, MAP3K2, MAP3K6 MEN1 4195/4885KMT2A 1524/4885KDM4E 1924/4885
US-20090281115-A1 INHIBITORS OF C-KIT AND USES THEREOF KIT, CHUK, MASTL MEN1 1273/4885KMT2A 773/4885KDM4E 702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.